Pfizer Alliance revenues decreased by 9.4% to $2.34B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.7%, from $2.11B to $2.34B. Over 4 years (FY 2021 to FY 2025), Alliance revenues shows an upward trend with a 4.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests successful leverage of external partnerships to drive sales, while a decrease may indicate expiring agreements or shifting commercial strategies.
Revenue generated through collaborative arrangements, co-promotion agreements, or profit-sharing partnerships with other...
Commonly reported by large pharma firms as 'collaboration revenue' or 'co-promotion income' in peer financial statements.
is_pfe_alliance_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.91B | $1.91B | $1.91B | $2.13B | $2.13B | $2.13B | $2.13B | $2.06B | $1.97B | $1.65B | $1.91B | $2.17B | $2.07B | $1.90B | $2.25B | $2.11B | $2.27B | $2.30B | $2.58B | $2.34B |
| QoQ Change | — | +0.0% | +0.0% | +11.6% | +0.0% | +0.0% | +0.0% | -3.5% | -4.5% | -16.4% | +16.1% | +13.7% | -4.8% | -8.1% | +18.4% | -6.0% | +7.6% | +1.1% | +12.4% | -9.4% |
| YoY Change | — | — | — | — | +11.6% | +11.6% | +11.6% | -3.5% | -7.8% | -22.9% | -10.5% | +5.4% | +5.1% | +15.5% | +17.7% | -2.7% | +10.0% | +20.9% | +14.8% | +10.7% |
| Segment | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Total Alliance revenues | $2.06B | $1.97B | $1.65B | $2.11B | $2.34B |
| Total | $2.06B | $1.97B | $1.65B | $2.11B | $2.34B |